E. David Crawford, MD, professor, Urologic and Radiation Oncology, head, Section of Urologic Oncology, University of Colorado at Denver, discusses rebiopsying for prostate cancer.
Each year in the U.S., 1.3-1.4 million biopsies are performed for prostate cancer, with only 240,000 leading to diagnoses. Crawford says that these men were biopsied for a reason and the question lingers as to whether or not rebiopsy. The need for a test to determine which men should be rebiopsied may have been answered by the ConfirmMDx test.
These methylation tests look for DNA changes in normal tissue on a biopsy that potentially was around the cancer, Crawford says. If the test is negative and no genes are methylated, the physician is presented with a 90%-plus positive predictive value that the man does not have cancer. Crawford says that if they test is negative and the man does have cancer, typically it is low-grade and would not be treated anyway. Crawford says this test has “unbelievable reach.”
<<< View more from the 7th Annual Interdisciplinary Prostate Cancer Congress